You are here: Home » 2025 » August » Archives for 18th

Nyxoah Reports Second Quarter Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter Financial and Operating Results
FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch

Mont–Saint–Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025.

Recent Financial and Operating Highlights

  • Received U.S. Food and Drug Administration (FDA) Pre–Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S.
  • Kicked off the U.S. commercial launch of the Genio system
  • DREAM pivotal study data published in the Journal of Clinical Sleep Medicine
  • Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth
  • Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025.

“This FDA approval represents a historic milestone for Nyxoah and marks the beginning of what we expect to be a transformational period for our company,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “Genio is now the first and only bilateral hypoglossal neurostimulation therapy approved in the United States, offering a truly differentiated solution for OSA patients who have been underserved by existing therapies. Our world–class commercial team is in place, and we have begun to execute on our commercial strategy.”

FDA PMA Approval

As previously disclosed, on August 8, 2025, the Company received FDA PMA for its Genio system, marking a historic milestone for Nyxoah. Genio’s unique design utilizes bilateral stimulation, and offers patients a leadless, full–body 1.5T and 3T MRI compatible, non–implanted battery solution, powered and controlled by a wearable component.

The Genio system’s FDA approval was supported by the high–quality, differentiated safety and efficacy data from the Company's DREAM pivotal trial, which demonstrated that Genio is efficacious regardless of a patient's sleeping position. This is a critical differentiator as on average, people sleep in a supine position between 35% and 40% of the night. The DREAM study measured position–specific outcomes and demonstrated a 66.6% median AHI reduction while patients slept in a supine position despite the fact that the number of airway obstructions can double in this position. This reduction compares favorably to the 71.0% reduction in AHI shown while patients slept in a non–supine position.

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
(in thousands)

      For the three months ended June 30   For the six months ended June 30  
      2025   2024   2025   2024
Revenue     1 340   771   2 404   1 992
Cost of goods sold     ( 490)   ( 281)   ( 896)   ( 735)
Gross profit     € 850   € 490   € 1 508   € 1 257
Research and Development Expense     (10 059)   (7 472)   (19 048)   (14 671)
Selling, General and Administrative Expense     (10 672)   (6 383)   (23 063)   (12 355)
Other income     31   58   115   249
Operating loss for the period     € (19 850)   € (13 307)   € (40 488)   € (25520)
Financial income     2 858   2 069   5 480   3 477
Financial expense     (3 337)   (1 445)   (7 579)   (2 436)
Loss for the period before taxes     € (20 329)   € (12 683)   € (42 587)   € (24479)
Income taxes     ( 278)   ( 441)   ( 404)   ( 551)
Loss for the period     € (20 607)   € (13 124)   € (42 991)   € (25030)
                   
Loss attributable to equity holders     € (20 607)   € (13 124)   € (42 991)   € (25030)
Other comprehensive loss                  
Items that may be subsequently reclassified to profit or loss (net of tax)                  
Currency translation differences     232   ( 82)   230   ( 22)
Total comprehensive loss for the year, net of tax     € (20 375)   € (13 206)   € (42 761)   € (25052)
Loss attributable to equity holders     € (20 375)   € (13 206)   € (42 761)   € (25052)
                   
Basic Loss Per Share (in EUR)     € (0.551)   € (0.428)   € (1.149)   € (0.843)
Diluted Loss Per Share (in EUR)     € (0.551)   € (0.428)   € (1.149)   € (0.843)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)
(in thousands)

        As at
        June 30
2025		   December 31 2024
ASSETS            
Non–current assets            
Property, plant and equipment       5 015   4 753
Intangible assets       51 407   50 381
Right of use assets       3 059   3 496
Deferred tax asset       76   76
Other long–term receivables       1 799   1 617
        € 61 356   € 60 323
Current assets            
Inventory       5 332   4 716
Trade receivables       1 330   3 382
Contract assets       1 508   −
Other receivables       3 014   2 774
Other current assets       944   1 656
Financial assets       20 257   51 369
Cash and cash equivalents       22 729   34 186
        € 55 114   € 98 083
Total assets       € 116 470   € 158 406
             
EQUITY AND LIABILITIES            
Share capital and reserves            
Share capital       6 431   6 430
Share premium       314 388   314 345
Share based payment reserve       11 645   9 300
Other comprehensive income       1 144   914
Retained loss       (260 211)   (217 735)
Total equity attributable to shareholders       € 73 397   € 113 254
             
LIABILITIES            
Non–current liabilities            
Financial debt       18 928   18 725
Lease liability       2 157   2 562
Provisions       404   1 000
Deferred tax liability       34   19
Contract liability       225   472
Other liability       379   845
        € 22 127   € 23 623
Current liabilities            
Financial debt       246   248
Lease liability       1 071   1 118
Trade payables       9 408   9 505
Current tax liability       3 990   4 317
Contract liability       460   117
Other liability       5 771   6 224
        € 20 946   € 21 529
Total liabilities       € 43 073   € 45 152
Total equity and liabilities       € 116 470   € 158 406

Revenue
Revenue was €1.3 million for the second quarter ending June 30, 2025, compared to €0.8 million for the second quarter ending June 30, 2024, representing a 74% year over year increase.

Cost of Goods Sold
Cost of goods sold was €490,000 for the second quarter ending June 30, 2025, representing a gross profit of €0.9 million, or gross margin of 63.4%. This compares to cost of goods sold of €281,000 in the second quarter ending June 30, 2024, for a gross profit of €0.5 million, or gross margin of 63.6%.

Research and Development
For the second quarter ending June 30, 2025, research and development (“R&D”) expenses were €10.0 million, versus €7.5 million for the second quarter ending June 30, 2024. The increase in research and development expenses was primarily due to higher R&D activities offset by a decrease in clinical study expenses.

Selling, General and Administrative
For the second quarter ending June 30, 2025, selling, general and administrative expenses were €10.7 million, versus €6.4 million for the second quarter ending June 30, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio system, including the Company’s overall scale–up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval.

Operating Loss
Total operating loss for the second quarter ending June 30, 2025 was €19.9 million, versus €13.3 million in the second quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, including the Company’s overall scale–up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval, and increased R&D activities offset by a decrease in clinical study expenses.

Cash Position
As of June 30, 2025, cash, cash equivalents and financial assets totaled €43.0 million, compared to €63.0 million at the end of March 31, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones.

Second Quarter 2025
Nyxoah’s financial report for the second quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Company management will host a conference call to discuss financial results on Monday, August 18, 2025, beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Events | Nyxoah Investors required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For Media
In United States
FINN Partners – Glenn Silver
[email protected]

For Media
Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

International/Germany
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Attachment


GLOBENEWSWIRE (Distribution ID 1001123459)

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025

INFORMATIONS RÉGLEMENTÉES

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025
La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit

Mont–Saint–Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui ses résultats financiers et d’exploitation pour le deuxième trimestre 2025.

Temps forts financiers et d’exploitation

  • Obtention de l'autorisation préalable à la mise sur le marché (PMA) de la Food and Drug Administration (FDA) américaine pour le système Genio, la première et unique thérapie de neurostimulation hypoglosse bilatérale approuvée aux États–Unis.
  • Lancement commercial du système Genio aux États–Unis.
  • Publication des données de l'étude pivot DREAM dans le Journal of Clinical Sleep Medicine.
  • Le chiffre d'affaires du deuxième trimestre 2025 s'est élevé à 1,3 million d'euros, contre 0,8 million d'euros au deuxième trimestre 2024, soit une croissance de 74 % en glissement annuel.
  • La trésorerie, les équivalents de trésorerie et les actifs financiers s'élevaient à 43,0 millions d'euros au 30 juin 2025, contre 63,0 millions d'euros au 31 mars 2025.

” Cette autorisation de la FDA représente une étape historique pour Nyxoah et marque le début de ce que nous espérons être une période de transformation pour notre entreprise “, a commenté Olivier Taelman, CEO de Nyxoah. ” Genio est désormais le premier et le seul traitement par neurostimulation hypoglossale bilatérale approuvé aux États–Unis, offrant une solution véritablement différenciée aux patients atteints d'AOS qui ont été mal desservis par les traitements existants. Notre équipe commerciale de classe mondiale est en place et nous avons commencé à mettre en œuvre notre stratégie commerciale. “

Autorisation PMA de la FDA

Comme annoncé précédemment, le 8 août 2025, la société a obtenu l'autorisation PMA de la FDA pour son système Genio, marquant ainsi une étape historique pour Nyxoah. La conception unique de Genio utilise une stimulation bilatérale et offre aux patients une solution sans fil, compatible avec l'IRM 1,5 T et 3 T pour tout le corps, sans implant et alimentée par une batterie, contrôlée par un composant portable.

L'autorisation de la FDA pour le système Genio s'appuie sur les données de haute qualité, différenciées en termes de sécurité et d'efficacité, issues de l'essai pivot DREAM mené par la société, qui a démontré l'efficacité de Genio quelle que soit la position de sommeil du patient. Il s'agit là d'un facteur de différenciation essentiel, car en moyenne, les personnes dorment en position couchée sur le dos entre 35 % et 40 % de la nuit. L'étude DREAM a mesuré les résultats spécifiques à la position et a démontré une réduction médiane de 66,6 % de l'IAH lorsque les patients dormaient en position couchée sur le dos, malgré le fait que le nombre d'obstructions des voies respiratoires puisse doubler dans cette position. Cette réduction est comparable à la réduction de 71,0 % de l'IAH observée lorsque les patients dormaient dans une position autre que couchée sur le dos.

ÉTATS CONSOLIDÉS DES PERTES ET AUTRES ÉLÉMENTS DU RÉSULTAT GLOBAL (non audités)

(en milliers)

      Pour la période de trois mois clôturée le 30 juin   Pour la période de six mois clôturée le 30 juin
      2025   2024   2025   2024  
Chiffre d’affaires     € 1 340   € 771   € 2 404   € 1 992  
Coût des biens vendus     ( 490)   ( 281)   ( 896)   ( 735)  
Bénéfice brut     € 850   € 490   € 1 508   € 1 257  
Frais de recherche et de développement     (10 059)   (7 472)   (19 048)   (14 671)  
Frais de vente, dépenses administratives et autres frais généraux     (10 672)   (6 383)   (23 063)   (12 355)  
Autres revenus d’exploitation     31   58   115   249  
Perte d’exploitation de la période     € (19 850)   € (13 307)   € (40 488)   € (25 520)  
Produits financiers     2 858   2 069   5 480   3 477  
Charges financières     (3 337)   (1 445)   (7 579)   (2 436)  
Perte de la période avant impôts     € (20 329)   € (12 683)   € (42 587)   € (24 479)  
Impôts sur le revenu     ( 278)   ( 441)   ( 404)   ( 551)  
Perte de la période     € (20 607)   € (13 124)   € (42 991)   € (25 030)  
                     
Perte attribuable aux actionnaires     € (20 607)   € (13 124)   € (42 991)   € (25 030)  
Autres éléments du résultat global                    
Eléments pouvant être reclassifiés en bénéfices ou en pertes (nets d’impôts)                    
Différences de conversion de devises     232   ( 82)   230   ( 22)  
Perte globale totale de la période, nette d’impôts     € (20 375)   € (13 206)   € (42 761)   € (25 052)  
Perte attribuable aux actionnaires     € (20 375)   € (13 206)   € (42 761)   € (25 052)  
                     
Perte par action (en €)     € (0,551)   € (0,428)   € (1,149)   € (0,843)  
Perte diluée par action (en €)     € (0,551)   € (0,428)   € (1,149)   € (0,843)  

ÉTAT CONSOLIDÉ DE LA SITUATION FINANCIÈRE (non audité)
(en milliers)

      Au
      30 juin
2025 		  31 décembre
2024
ACTIFS          
Actifs non courants          
Immobilisations corporelles     5 015   4 753
Immobilisations incorporelles     51 407   50 381
Droit d’utilisation des actifs     3 059   3 496
Actif d’impôts différés     76   76
Autres créances à long terme     1 799   1 617
      €61356   € 60 323
Actifs courants          
Stocks     5 332   4 716
Créances commerciales     1 330   3 382
Actifs liés à des contrats     1 508   −
Autres créances     3 014   2 774
Autres actifs courants     944   1 656
Actifs financiers     20 257   51 369
Trésorerie et équivalents de trésorerie     22 729   34 186
      € 55114   € 98 083
Total de l’actif     € 116470   € 158 406
           
CAPITAUX PROPRES ET PASSIFS          
Capital et réserves          
Capital     6 431   6 430
Prime d’émission     314 388   314 345
Réserve pour paiement fondé sur des actions     11 645   9 300
Autres éléments du résultat global     1 144   914
Résultats reportés     (260211)   (217 735)
Total des capitaux propres attribuables aux actionnaires     € 73397   € 113 254
           
PASSIFS          
Passifs non courants          
Dettes financières     18 928   18 725
Passifs locatifs     2 157   2 562
Provisions     404   1 000
Passif d’impôts différés     34   19
Responsabilité contractuelle     225   472
Autres passifs     379   845
      € 22 127   € 23 623
Passifs courants          
Dettes financières     246   248
Passifs locatifs     1 071   1 118
Dettes commerciales     9 408   9 505
Passif d’impôts exigibles     3 990   4 317
Responsabilité contractuelle     460   117
Autres passifs     5 771   6 224
      € 20 946   € 21 529
Total du passif     € 43 073   € 45 152
Total des capitaux propres et du passif     € 116470   € 158 406

Revenus

Le chiffre d'affaires s'est élevé à 1,3 million d'euros pour le deuxième trimestre clos le 30 juin 2025, contre 0,8 million d'euros pour le deuxième trimestre clos le 30 juin 2024, soit une augmentation de 74 % en variation annuelle.

Coût des marchandises vendues
Le coût des marchandises vendues s'est élevé à 490 000 € pour le deuxième trimestre clos le 30 juin 2025, ce qui représente un bénéfice brut de 0,9 million d'euros, soit une marge brute de 63,4 %. Ce chiffre est à comparer au coût des marchandises vendues de 281 000 € au deuxième trimestre clos le 30 juin 2024, pour une marge brute de 0,5 million d'euros, soit une marge brute de 63,6 %.

Recherche et développement
Pour le deuxième trimestre clos le 30 juin 2025, les dépenses de recherche et développement (« R&D ») se sont élevées à 10,0 millions d'euros, contre 7,5 millions d'euros pour le deuxième trimestre clos le 30 juin 2024. L'augmentation des dépenses de recherche et développement est principalement due à l'intensification des activités de R&D, compensée par une diminution des dépenses liées aux études cliniques.

Frais commerciaux, généraux et administratifs
Pour le deuxième trimestre clos le 30 juin 2025, les frais commerciaux, généraux et administratifs se sont élevés à 10,7 millions d'euros, contre 6,4 millions d'euros pour le deuxième trimestre clos le 30 juin 2024. L'augmentation des frais de vente, généraux et administratifs est principalement due à une hausse des coûts liés à la commercialisation du système Genio, notamment les préparatifs généraux de la société en vue de la commercialisation du système Genio aux États–Unis dans le cadre de l'obtention de l'autorisation de la FDA.

Perte d'exploitation
La perte d'exploitation totale pour le deuxième trimestre clos le 30 juin 2025 s'est élevée à 19,9 millions d'euros, contre 13,3 millions d'euros au deuxième trimestre 2024. Cette augmentation s'explique par la hausse des frais commerciaux, généraux et administratifs liés à la commercialisation du système Genio, notamment les préparatifs généraux de la société en vue de la commercialisation du système Genio aux États–Unis suite à l'obtention de l'autorisation de la FDA, ainsi que par l'intensification des activités de R&D, compensées par une baisse des dépenses liées aux études cliniques.

Position de trésorerie
Au 30 juin 2025, la trésorerie et les actifs financiers s'élevaient à 43,0 millions d'euros, contre 63,0 millions d'euros au 31 mars 2025. La Société dispose également d'une facilité de crédit à terme d'un montant restant disponible de 27,5 millions d'euros, qui peut être utilisée en deux tranches égales sous réserve de la réalisation d'objectifs en matière de chiffre d'affaires et d'autres objectifs financiers.

Deuxième Trimestre 2025

Le rapport financier de Nyxoah pour le deuxième trimestre 2025, y compris les détails des résultats consolidés audités, sont disponibles sur la page investisseurs du site web de Nyxoah (https://investors.nyxoah.com/financials).

Conférence téléphonique et webcast

Le management de la Société organisera une conférence téléphonique pour discuter ses résultats financiers le lundi 18 août 2025, à 22h30 CET / 16h30 ET.

La retransmission de la conférence téléphonique sera accessible sur la page Investor Relations du site web de Nyxoah ou par le biais de ce lien : Nyxoah's Q2 2025 Earnings Call Webcast. Pour ceux qui n'ont pas l'intention de poser une question au Management, la Société recommande d'écouter la webdiffusion.

Si vous avez l'intention de poser une question, veuillez utiliser le lien suivant : Nyxoah's Q2 2025 Earnings Call. Après l'inscription, un courriel sera envoyé, comprenant les détails de la connexion et un code d'accès unique à la conférence téléphonique nécessaire pour rejoindre l'appel en direct. Pour s'assurer que vous êtes connecté avant le début de la conférence, la Société suggère de s'inscrire au moins 10 minutes avant le début de l'appel.

Le webcast archivé pourra être réécouté peu après la clôture de la conférence.

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la Food and Drug Administration (FDA) américaine pour un sous–groupe de patients atteints d'AOS modérée à sévère avec un indice d'apnée–hypopnée (IAH) supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur ordonnance.

Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Medias

Aux États–Unis
FINN Partners – Alyssa Paldo
[email protected]

International / Allemagne
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Belgique / France
Backstage Communication – Gunther De Backer
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001123459)

24/7 concierge: Zoom’s agentic AI and virtual agent now extends to Zoom Phone, helping businesses capture more calls and opportunities

  • Zoom Virtual Agent expands to Zoom Phone, enabling a new concierge use case that delivers personalized support with agentic concierge capabilities to automate routine calls and streamline frontline service across departments
  • Zoom AI Companion enhances agentic scheduling to coordinate meetings end–to–end, finding the best time, contacting attendees, tracking responses, and recommending next steps without the back–and–forth
  • Zoom Hub launches, providing a centralized workspace to create, find, and manage Zoom files
  • Zoom Team Chat adds AI Companion to mobile for easier catch–up, and quick document summaries without needing to open the file in the Zoom Workplace desktop app, saving time and boosting productivity

SAN JOSE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced a new concierge use case for Zoom Virtual Agent, now integrated with Zoom Phone, giving businesses a smarter way to answer calls and better support callers from the start. Zoom also announced the launch of Zoom Hub, a centralized content center to help users organize, manage, and create Zoom assets, and enhanced AI features across Zoom Meetings and Team Chat to help teams work faster and stay aligned in real time.

A 24/7 AI receptionist that does more than route calls

Zoom Virtual Agent, now integrated with Zoom Phone, provides an elevated concierge experience that goes beyond basic call answering services or auto–attendants. As your newest front desk team member, the concierge greets callers, speaks naturally, processes input, and initiates the most appropriate next step. From booking appointments to providing updates and routing to the right person without phone trees or long hold times, it helps organizations reduce missed calls and deliver a more professional first impression.

“When someone calls your business, it should feel easy and personal from the first hello. By combining AI that can listen, understand, and take action with the reach of Zoom Phone, our concierge virtual agent provides seamless and personalized support to all callers,” said Smita Hashim, chief product officer at Zoom. “Whether a customer is calling to schedule an appointment, check an order status, or check product availability, Zoom’s concierge is available 24×7 and can deliver answers instantly, escalating to live employees only when needed. The result is a faster, more personalized, and more scalable experience for everyone.”

Admins can save time and avoid tech headaches by easily deploying the concierge within minutes using a no–code configuration. By uploading documents or pointing to a website, teams can quickly train the concierge to greet callers and respond to real–world questions. Built to work with diverse audiences, it supports natural, multilingual conversations in English, Spanish, French, German, Portuguese, and Japanese, with more on the way, and is available 24/7 so callers get a fast, consistent experience any time of the day.

Zoom Virtual Agent (ZVA) concierge supports a wide range of use cases, including:

  • Healthcare: In fast–paced care settings, ZVA concierge can help patients get connected with the care they need quickly. It can route calls to the right department, answer common questions like “Are you accepting new patients?”, and let patients book appointments by phone, even after hours, freeing staff to focus on care delivery.
  • Retail: When customers call with specific needs like finding the right product for a project or checking if an item is in stock, ZVA concierge can answer their questions, confirm if an item is in stock (even down to the aisle), schedule pickup, and more, all without requiring human assistance.
  • Manufacturing: For companies juggling service requests and product support, ZVA concierge can capture customer requests, guide them through troubleshooting over the phone, and direct them to the right team, day or night, without manual intake.
  • Financial services: Personalized service is critical in financial conversations. ZVA concierge can greet clients, gather information about why they’re calling, and resolve the request on the spot, like providing application updates, or connect them to the right advisor with all the details already captured, reducing wait times while providing a high–touch experience.

The Zoom Virtual Agent phone concierge capability is available today. To learn more or request a demo, visit zoom.com.

Agentic meeting scheduling without the back and forth

The AI Companion meeting scheduling skill uses agentic AI to eliminate the friction of finding a time that works for everyone, whether scheduling with colleagues or external partners. Instead of juggling calendars, tracking multiple time zones, and managing out–of–office notices, AI Companion instantly analyzes all of these factors to surface the most convenient options.

Once a preferred time is selected, AI Companion takes over the coordination process, reaches out to invitees directly, sends meeting requests, and keeps a real–time pulse on responses, whether via email or Zoom Team Chat. If a proposed time no longer works, it immediately suggests an alternative, ensuring the conversation keeps moving and the meeting is confirmed quickly.

This end–to–end automation prevents scheduling delays and missed opportunities. AI Companion acts as a dedicated meeting coordinator, removing tedious back–and–forth, reducing scheduling errors, and giving teams more time to focus on the discussion itself, not the logistics.

A new asset hub to stay organized and work efficiently

Zoom Hub, now generally available, introduces a streamlined way for users to stay organized and take action across Zoom Workplace. As a central destination within Zoom Workplace, Zoom Hub works with AI Companion to help users create content more efficiently, while also bringing together Zoom meeting recordings, meeting summaries, docs, whiteboards, clips, and more, eliminating the need to jump between tools or hunt for files.

  • Stay organized, with the ability to view your Zoom assets in one place and organize assets by folder.
  • Catch up and prepare for meetings easily by searching for files by meeting.
  • Kickstart drafts with AI Companion in Zoom Hub, including Zoom docs or data tables, whiteboards, and clips.

A chat experience that works smarter with AI

Zoom Team Chat users can now work smarter on the go with AI Companion built right into the Team Chat compose bar and a refreshed mobile experience, making it easier to draft messages and catch up on unread messages. When using Team Chat in the Zoom Workplace desktop app, users can now see a summary of a document by selecting the summarize icon when hovering over the file card without having to open the file, helping save more time.

Additionally, to help improve AI Companion’s ability to handle agentic tasks like meeting scheduling and translating conversations into actionable outcomes for users, Zoom will be among the first to integrate OpenAI’s GPT–5 into its AI stack.

Zoom AI Companion’s new agentic capabilities and enhancements help users save time in the workday and are included at no additional cost with paid Zoom Workplace plans. These updates reinforce Zoom’s commitment to building a truly AI–first collaboration platform that helps teams work faster, stay aligned, and focus on what matters most.

To learn more about Zoom Workplace, visit the Zoom website.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Travis Isaman
[email protected]


GLOBENEWSWIRE (Distribution ID 9514089)

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

                                      

Extrovis AG
Bahnhof Park 4
6340, Baar, Switzerland		 Media Relations Contact
Madhu Marur
[email protected]

                                        

Press Release

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Baar, Switzerland; August 14, 2025

Extrovis AG, a global pharmaceutical company focused on research–driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).

Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

“This product generic launch marks a key milestone in our commitment to increasing patient access and long–term value creation for the U.S. healthcare system. Our partnership with Dr. Reddy’s helps ensure that patients and healthcare providers in the United States have continued access to a high–quality and cost–effective product,” said Hans R. Kamma Co–CEO and Chief Strategy Officer of Extrovis AG.

“Dr. Reddy’s brings deep expertise in commercialization and distribution within the U.S. market,” added Raghavendra Rao PV, Chief Financial Officer of Extrovis AG. “This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly.”

The partnership reinforces Extrovis’ strategy to extend the reach of its therapeutics while advancing long–term affordability and sustainability in healthcare.

Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30–gram tube for topical use only. Please click here to see the full prescribing information.

                                                                                     

Carac® is a trademark of Extrovis AG

……………………………………………………………………………………..……………………………………………………………………………………………………………………

About Dr. Reddy’s
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

About Extrovis AG
Extrovis AG is a Switzerland–based global biopharmaceutical company committed to developing and commercializing high–quality therapies for unmet and under–addressed medical needs. With R&D and manufacturing operations in the USA, Italy, Hungary, and India, Extrovis delivers innovative, differentiated products across key therapeutic areas. Backed by strong R&D capabilities, regulatory expertise, and a robust global quality framework, the company advances its mission to improve patient outcomes and expand access to essential health care products worldwide. For more information, log on to: http://www.extrovis.com

………………………………………………………………………………………………………………………………………………………

Disclaimer: This press release may include statements of future expectations and other forward–looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward–looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward–looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID–19). The company assumes no obligation to update any information contained herein.

 

Attachment


GLOBENEWSWIRE (Distribution ID 1001123392)

BTCS Offers Shareholders a $0.05 per share “Bividend” – a Blockchain Dividend Payable in Ethereum

SILVER SPRING, MD, Aug. 18, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology–focused company, short for Blockchain Technology Consensus Solutions, today announced that it is paying shareholders a one–time blockchain dividend, or “Bividend” of $0.05 per share in Ethereum (ETH). The Bividend marks the first time a public company has paid a dividend in ETH.

BTCS is also offering a one–time $0.35 per share loyalty payment, payable solely in ETH, to shareholders who move their shares to book entry with the Company’s transfer agent and keep them there for at least 120 days, which should reduce the ability of shares to be lent for short–selling purposes. Together, the Bividend and loyalty payment total $0.40 per share in ETH for eligible shareholders. Officers, directors, and employees of the Company, as well as Series V Preferred holders, are not eligible for the $0.35 per share loyalty payment.

“We are paying the Bividend and loyalty payment to thank our long–term shareholders and empower them to take control of and protect their investment,” said Charles Allen, CEO of BTCS. “By moving to book entry, our shareholders receive a tangible benefit and prevent their shares from being lent to short sellers, protecting against market manipulation and forcing institutional short sellers to either cover or call in existing short positions.”

“Right now, short sellers are betting against BTCS because they expect us to sell a significant number of shares to raise capital,” said Allen. “As the largest shareholder of BTCS, let me be perfectly clear: my goal is to grow our market cap primarily through share price appreciation, not toxic dilution. I have and will continue to aggressively protect our company and our shareholders from institutions that short our stock to profit at your expense.”

BTCS intends to pay the $0.05 per share ETH Bividend based on ETH’s price on the record date. Investors who do not elect to receive the ETH Bividend will receive a cash dividend of $0.05 per share.

As of August 15, 2025, BTCS stock closed at $4.41 per share, despite holding approximately $6.65 per share in cash and digital assets, illustrating the compelling value proposition for our shareholders. This underscores the disconnect between our share price and the intrinsic value of our underlying assets and operating business, making it an appropriate time to reward shareholders with this distribution.

Shareholders should consult their tax advisors regarding the tax implications of receiving this distribution and the loyalty payment.

“We have a history of rewarding our shareholders for their loyalty: in addition to paying a Bividend in Bitcoin in 2022, we are the first public company in the world to pay a Bividend in Ethereum,” said Allen. “This is a moment we have long anticipated since our February 2015 purchase of bividend.com.”

How can shareholders participate in the Bividend?

To receive the Bividend in ETH, prior to the record date, BTCS shareholders must: (1) complete the opt–in form available through bividend.com, and (2) transfer their shares to our transfer agent, Equity Stock Transfer, by following the provided instructions. Any shareholder who does not opt–in to receive their Ethereum Bividend will automatically receive the dividend in USD.

BTCS has set a record date of September 26, 2025, allowing ample time for shareholders to complete the opt–in process and move their shares before the record date.

The Bividend, and the equivalent cash dividend, will be paid as soon as possible after the record date.

How can shareholders receive the loyalty payment?

In addition to the Bividend, BTCS will issue a one–time loyalty payment of $0.35 per share to Common Stock shareholders who hold their shares with the Company’s transfer agent from September 26, 2025, through January 26, 2026. Shareholders need to complete the opt–in form and transfer their shares to our transfer agent, Equity Stock Transfer, to receive the loyalty payment.

Payable solely in ETH, the loyalty payment is designed to reward long–term shareholders who demonstrate continued support for BTCS’s vision and strategy and potentially limit predatory short–selling practices.

The loyalty payment will be paid as soon as possible after January 26, 2026.

Full details are outlined on bividend.com and disclosed in a Form 8–K filed with the Securities and Exchange Commission on August 18, 2025. Series V Preferred shareholders will also receive a $0.05 cash dividend and are not eligible for the loyalty payment.

CEO Charles Allen recently published a thought leadership piece entitled “Why Fake Shares and Forced Lending Must Be Outlawed” that can be found here.

About BTCS:
BTCS Inc. (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, is a U.S.–based Ethereum–first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance (“DeFi”) and traditional finance (“TradFi”) mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield–focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.

Cautionary Note Regarding Forward–Looking Statements
Certain statements in this press release constitute “forward–looking statements” within Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 including statements regarding our ability to successfully implement and pay the Bividend and loyalty payment, growth in our market cap and appreciation in stock price. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward–looking statements. While the Company believes these forward–looking statements are reasonable, undue reliance should not be placed on any such forward–looking statements, which are based on information available to us on the date of this release. These forward–looking statements are based upon assumptions and are subject to various risks and uncertainties, regulatory issues, unanticipated issues on Nasdaq with respect to implementing the Bividend or issues implementing the loyalty payment, as well as risks set forth in the Company’s filings with the Securities and Exchange Commission including its Form 10–K for the year ended December 31, 2024 which was filed on March 20, 2025. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events or otherwise, except as required by law.

For more information follow us on:
X: https://x.com/NasdaqBTCS
LinkedIn: https://www.linkedin.com/company/nasdaq–btcs
Facebook: https://www.facebook.com/NasdaqBTCS

Investor Relations:
Charles Allen – CEO
X: @Charles_BTCS
Email: [email protected]


GLOBENEWSWIRE (Distribution ID 9513644)

Lantronix-Lösung unterstützt die von der US-Armee zugelassenen Teal Drones, ein Unternehmen der Red Cat Holdings, und erschließt Wachstumschancen für sichere Edge-KI

IRVINE, Kalifornien, Aug. 18, 2025 (GLOBE NEWSWIRE) — Lantronix Inc.– (NASDAQ: LTRX), ein weltweit führender Anbieter von IoT–Lösungen für Computer und Konnektivität, die Edge–KI–Anwendungen unterstützen, gab heute bekannt, dass seine TAA– und NDAA–konforme Lösung von Teal Drones, einem Unternehmen von Red Cat Holdings Inc. (NASDAQ: RCAT), für die Produktion seiner Black–Widow™–Drohnen im Rahmen des Short–Range–Reconnaissance–(SRR)–Programms der US–Armee ausgewählt wurde. Lantronix hat bereits mit der Produktion begonnen, was frühzeitige Umsatztransparenz ermöglicht und die Rolle von Lantronix als vertrauenswürdiger Technologiepartner für unternehmenskritische Verteidigungsanwendungen unterstreicht.

Die auf dem Prozessor Qualcomm® Dragonwing™ QRB5165 basierende Lantronix–Lösung bietet fortschrittliche Edge–KI–Verarbeitung und erfüllt gleichzeitig die strengen Sicherheitsanforderungen der USA. Sie ermöglicht die vollständige TAA– und NDAA–Konformität für den Einsatz in sensiblen Missionen des Verteidigungsministeriums. Die Kombination aus KI–Leistung und Compliance verschafft Lantronix einen nachhaltigen Vorteil auf dem schnell wachsenden Markt für Verteidigungs– und autonome Systeme.

Als Teil einer ausgewählten Gruppe von kleinen, von Blue UAS zugelassenen Anbietern unbemannter Luftsysteme müssen Teal Drones für den Einsatz durch das US–Verteidigungsministerium strenge Cybersicherheits–, Betriebs– und Sicherheitsstandards erfüllen. Die konforme Lösung von Lantronix ermöglicht es Teal, diese Anforderungen zu erfüllen und seine Black–Widow–Drohnen für den Einsatz in Frontmissionen zu positionieren.

„Black–Widow–Drohnen definieren die Möglichkeiten kleiner unbemannter Systeme neu und bieten den heutigen Soldaten Echtzeitinformationen und den operativen Vorsprung, den sie auf dem modernen Schlachtfeld brauchen“, sagt Jeff Thompson, CEO von Red Cat. „Die Lösung von Lantronix ermöglicht es uns, die strengen TAA– und NDAA–Konformitätsstandards der US–Armee im Rahmen des SRR–Programms zu erfüllen – ein Maß an Sicherheit, das nur wenige Anbieter bieten können.“

Der globale Drohnenmarkt soll bis 2030 voraussichtlich 57,8 Milliarden US–Dollar erreichen (Global Drone Market Report 2025–2030 von Drone Industry Insights). Die Präsenz von Lantronix im Segment der sicheren Verteidigungs– und kommerziellen Drohnen schafft mehrjährige Wachstumschancen mit hohen Margen.

—–„Lantronix hat sich als führendes Unternehmen im Edge–KI–Markt etabliert und bietet innovative, Compliance–orientierte Lösungen für den wachsenden Drohnensektor“, sagt Saleel Awsare, CEO und Präsident von Lantronix. „Unsere Zusammenarbeit mit Teal Drones unterstreicht unsere Fähigkeit, sichere, leistungsstarke Produkte in großem Maßstab auf den Markt zu bringen und so langfristige Chancen mit führenden globalen Marken zu schaffen.“

—Die Lösungen und Engineering Services von Lantronix kombinieren eingebettete Computertechnologie, Compliance–Expertise und flexiblen Software–Support, um die Produktentwicklung der Kunden zu beschleunigen. Dieser skalierbare Plattformansatz ermöglicht nicht nur eine schnelleMarkteinführung von Teal Drones, sondern versetzt Lantronix auch in die Lage, zukünftige Verteidigungs– und industrielle IoT–Programme zu unterstützen, die TAA– und NDAA–Konformität erfordern.

Weitere Informationen zu den Engineering Services, SOM–Lösungen und zusätzlichen Drohnenanwendungen von Lantronix finden Sie auf Lantronix.com.

Über Lantronix   

Lantronix Inc. (Nasdaq: LTRX) ist ein weltweit führender Anbieter von Edge–KI– und industriellen IoT–Lösungen und bietet intelligentes Computing, sichere Konnektivität sowie Remote–Management für unternehmenskritische Anwendungen. Lantronix bedient wachstumsstarke Märkte, darunter Smart Cities, Unternehmens–IT sowie unbemannte kommerzielle und militärische Systeme, und ermöglicht seinen Kunden, ihre Betriebsabläufe zu optimieren sowie die digitale Transformation zu beschleunigen. Sein umfassendes Portfolio an Hardware, Software und Diensten unterstützt Anwendungen von sicherer Videoüberwachung und intelligenter Versorgungsinfrastruktur bis hin zu robustem Out–of–Band–Netzwerkmanagement. Indem Lantronix Intelligenz an den Netzwerkrand bringt, hilft es Unternehmen, in der heutigen KI–gesteuerten Welt Effizienz, Sicherheit und einen Wettbewerbsvorteil zu erreichen.

Weitere Informationen finden Sie auf der Website von Lantronix.

Über Red Cat Holdings Inc.

Red Cat (Nasdaq: RCAT) ist ein in den USA ansässiger Anbieter fortschrittlicher Drohnen– und Roboterlösungen für alle Bereiche der Verteidigung und nationalen Sicherheit. Über seine hundertprozentigen Tochtergesellschaften Teal Drones und FlightWave Aerospace entwickelt Red Cat in den USA hergestellte Hardware und Software, die Militär–, Regierungs– und öffentliche Sicherheitsoperationen in der Luft, zu Land und zur See unterstützt. Seine Systemfamilie, angeführt von Black Widow™, bietet unübertroffene taktische Fähigkeiten in kleinen unbemannten Flugzeugsystemen. Red Cat expandiert über Blue OPS, Inc. in den maritimen Bereich und entwickelt außerdem Innovationen im Bereich unbemannter Überwasserschiffe und autonomer Unterwasserfahrzeuge. Das Unternehmen liefert integrierte Plattformen zur Verbesserung der Sicherheit und Effektivität von Missionen in mehreren Bereichen. Weitere Informationen finden Sie unter www.redcat.red.

©2025 Lantronix, Inc. Alle Rechte vorbehalten. Lantronix ist eine eingetragene Marke. Andere Marken und Markennamen sind Eigentum der jeweiligen Inhaber.

„Safe Harbor“–Erklärung gemäß dem Private Securities Litigation Reform Act von 1995: Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne der US–Bundeswertpapiergesetze, insbesondere Aussagen in Bezug auf Produkte oder die Geschäftsführung von Lantronix.  Diese zukunftsgerichteten Aussagen basieren auf unseren aktuellen Erwartungen und unterliegen erheblichen Risiken und Ungewissheiten, die dazu führen können, dass unsere tatsächlichen Ergebnisse, zukünftigen Geschäfts–, Finanz– oder Leistungsergebnisse erheblich von unseren historischen Ergebnissen oder von denen, die in den zukunftsgerichteten Aussagen in dieser Pressemitteilung ausgedrückt oder impliziert werden, abweichen. Zu den potenziellen Risiken und Ungewissheiten gehören unter anderem Faktoren wie die Auswirkungen negativer oder sich verschlechternder regionaler und weltweiter wirtschaftlicher Bedingungen oder Marktinstabilität auf unser Geschäft, einschließlich der Auswirkungen auf die Kaufentscheidungen unserer Kunden; unsere Fähigkeit, Unterbrechungen in unseren Lieferketten und denen unserer Zulieferer und Verkäufer aufgrund der COVID–19–Pandemie oder anderer Ausbrüche, Kriege und jüngster Spannungen in Europa, Asien und dem Nahen Osten oder anderer Faktoren abzumildern; künftige Reaktionen auf und Auswirkungen von Krisen im Bereich der öffentlichen Gesundheit; Risiken im Bereich der Cybersicherheit; Änderungen geltender US–amerikanischer und ausländischer Cybersicherheitsrisiken; Änderungen der geltenden Gesetze, Vorschriften und Zölle der US–amerikanischen und ausländischer Regierungen; unsere Fähigkeit, unsere Übernahmestrategie erfolgreich umzusetzen oder erworbene Unternehmen zu integrieren; Schwierigkeiten und Kosten des Schutzes von Patenten und anderen Eigentumsrechten; die Höhe unserer Verschuldung, unsere Fähigkeit, unsere Verschuldung zu bedienen, und die Beschränkungen in unseren Schuldverträgen; sowie alle weiteren Faktoren, die in unserem Jahresbericht auf Formblatt 10–K für das am 30. Juni 2024 zu Ende gegangene Geschäftsjahr enthalten sind, der am 9. September 2024 bei der US–amerikanischen Börsenaufsichtsbehörde (der „SEC“) eingereicht wurde, einschließlich des Abschnitts „Risikofaktoren“ in Punkt 1A von Teil I dieses Berichts, sowie in unseren anderen öffentlichen Einreichungen bei der SEC.  Weitere Risikofaktoren können von Zeit zu Zeit in unseren zukünftigen Veröffentlichungen genannt werden. Darüber hinaus können die tatsächlichen Ergebnisse aufgrund zusätzlicher Risiken und Unsicherheiten, die wir derzeit nicht kennen oder die wir derzeit nicht als wesentlich für unser Geschäft einschätzen, abweichen. Aus diesen Gründen sind die Anleger dazu angehalten, zukunftsgerichtete Aussagen mit der gebotenen Vorsicht zur Kenntnis zu nehmen. Die in dieser Mitteilung enthaltenen zukunftsgerichteten Aussagen beziehen sich ausschließlich auf den Zeitpunkt ihrer Veröffentlichung. Wir lehnen ausdrücklich jede Absicht oder Verpflichtung ab, zukunftsgerichtete Aussagen nach diesem Datum zu aktualisieren, es sei denn, dies ist gesetzlich vorgeschrieben oder durch die Regeln der Nasdaq Stock Market LLC festgelegt. Wenn wir zukunftsgerichtete Aussagen aktualisieren oder korrigieren, sollten Anleger nicht davon ausgehen, dass wir weitere Aktualisierungen oder Korrekturen vornehmen werden.

Lantronix–Medienkontakt:         
[email protected]
949–212–0960 

Lantronix – Analysten– und Anlegerkontakt:         
[email protected]


GLOBENEWSWIRE (Distribution ID 9513766)

Solução Lantronix Capacita a Teal Drones, uma empresa da Red Cat Holdings Co. Aprovada pelo Exército dos EUA, Desbloqueando uma Oportunidade de Crescimento da Edge AI Segura

IRVINE, Califórnia, Aug. 18, 2025 (GLOBE NEWSWIRE) — A Lantronix Inc.(NASDAQ: LTRX), líder global em soluções de IoT de computação e conectividade que alimentam aplicativos Edge AI, anunciou hoje que sua solução compatível com TAA e NDAA foi selecionada pela Teal Drones, uma Red Cat Holdings Inc. (NASDAQ: RCAT), para a produção dos seus drones Black Widow™ no âmbito do Programa de Reconhecimento de Curto Alcance (SRR) do Exército dos EUA. A Lantronix já deu início às primeiras entregas, proporcionando visibilidade antecipada da receita e ressaltando o papel da Lantronix como parceira de tecnologia confiável para aplicações de defesa de missão crítica.

A solução Lantronix, baseada no processador Qualcomm® Dragonwing™ QRB5165, oferece processamento Edge AI avançado, atendendo aos rigorosos requisitos de segurança dos EUA, para total conformidade com TAA e NDAA, para implantação em missões sigilosas do Departamento de Defesa (DOD). A combinação do desempenho com a conformidade com IA oferece uma vantagem sustentável para a Lantronix no mercado de sistemas de defesa e autônomos em rápida expansão.

Como parte de um grupo seleto de pequenos fornecedores de Sistemas Aéreos Não Tripulados (sUAS) aprovados pela Blue UAS, a Teal Drones deve atender a rigorosos padrões de segurança cibernética, operacional e de segurança para uso do DoD. A solução compatível da Lantronix permite que a Teal Drones atenda a esses requisitos, posicionando seus drones Black Widow para implantação em missões de linha de frente.

“Os drones Black Widow estão redefinindo o que é possível para pequenos sistemas não tripulados, fornecendo aos combatentes de hoje inteligência em tempo real e a vantagem operacional necessária no campo de batalha moderno”, disse Jeff Thompson, CEO da Red Cat. “A solução da Lantronix nos permite atender aos rigorosos padrões de conformidade TAA e NDAA do Exército dos EUA sob o Programa SRR — um nível de garantia que poucos provedores podem igualar.”

Com o mercado global de drones projetado para atingir US $57,8 bilhões até 2030 (Drone Industry Insights ’2025–2030 Global Drone Market Report), a presença da Lantronix no segmento de defesa e drones comerciais seguros cria oportunidades de crescimento plurianuais e de alta margem.

“A Lantronix se estabeleceu como líder no mercado de Edge AI, oferecendo soluções inovadoras e orientadas para a conformidade para o crescente setor de drones”, disse Saleel Awsare, CEO e presidente da Lantronix. “Nossa colaboração com a Teal Drones ressalta nossa capacidade de levar produtos seguros e de alto desempenho ao mercado em escala, criando oportunidades de longo prazo com as principais marcas globais.”

As soluções e os Serviços de Engenharia da Lantronix combinam tecnologia de computação incorporada, experiência em conformidade e suporte de software flexível para acelerar o desenvolvimento de produtos do cliente. Além de agilizar o lançamento dos produtos no mercado, essa abordagem de plataforma escalável da Teal Drones também permite que a Lantronix possa apoiar futuros programas de defesa e IoT industrial que exigem conformidade com TAA e NDAA.

Saiba mais sobre os Serviços de Engenharia, soluções SOM e Aplicações de Drones adicionais na Lantronix.com.

Sobre a Lantronix   

A Lantronix Inc. (Nasdaq: LTRX) é líder global em soluções Edge AI e Industrial IoT, oferecendo computação inteligente, conectividade segura e gerenciamento remoto para aplicativos de missão crítica. Atendendo a mercados de alto crescimento, incluindo cidades inteligentes, TI corporativa e sistemas comerciais e de defesa não tripulados, a Lantronix permite que os clientes otimizem as operações e acelerem a transformação digital. Seu portfólio abrangente de hardware, software e serviços capacita aplicativos, desde os de vigilância por vídeo segura e infraestrutura de serviços públicos inteligentes até o gerenciamento de rede resiliente fora de banda. Com a oferta de inteligência para a borda da rede, a Lantronix ajuda as organizações a alcançar eficiência, segurança e uma vantagem competitiva no mundo atual impulsionado pela IA.

Para mais informação, visite Site da Lantronix.

Sobre a Red Cat Holdings Inc.

A Red Cat (Nasdaq: RCAT) é uma fornecedora baseada nos EUA de soluções avançadas de drones e robôs para todos os domínios para defesa e segurança nacional. Por meio das suas subsidiárias integrais, Teal Drones e FlightWave Aerospace, a Red Cat desenvolve hardware e software fabricados nos Estados Unidos que apoiam operações militares, governamentais e de segurança pública no ar, na terra e no mar. Sua Família de Sistemas, liderada pela Black Widow™, oferece capacidades táticas incomparáveis em pequenos sistemas de aeronaves não tripuladas (sUAS). Expandindo para o domínio marítimo por meio da Blue OPS, Inc., a Red Cat também está inovando em embarcações de superfície não tripuladas (USVs) e veículos subaquáticos autônomos (AUVs), fornecendo plataformas integradas projetadas para aprimorar a segurança e a eficácia da missão em vários domínios. Saiba mais em www.redcat.red.

©2025 Lantronix, Inc. Todos os direitos reservados. Lantronix é uma marca comercial registrada. Todas as outras marcas comerciais são de propriedade de seus respectivos proprietários.

“Declaração Safe Harbor sob a Lei Private Securities Litigation Reform Act de 1995: Este comunicado contém declarações de previsão de acordo com as leis federais de valores mobiliários, incluindo, sem limitação, declarações relacionadas aos produtos e equipe de liderança da Lantronix. Essas declarações de previsão são baseadas nas nossas expectativas atuais e estão sujeitas a riscos e incertezas substanciais que podem fazer com que nossos resultados reais, negócios futuros, condição financeira ou desempenho, sejam substancialmente diferentes dos nossos resultados históricos, expressos ou implícitos, em qualquer declaração prospectiva contida neste comunicado de imprensa. Os riscos e incertezas potenciais incluem, mas não estão limitados a, fatores tais como os efeitos das condições econômicas regionais e mundiais negativas ou piores, ou instabilidade do mercado nos nossos negócios, incluindo efeitos sobre as decisões de compra por parte dos nossos clientes; nossa capacidade de mitigar qualquer interrupção nas cadeias de fornecimento dos nossos fornecedores devido à pandemia de COVID–19 ou outros surtos, guerras e tensões recentes na Europa, Ásia e Oriente Médio, ou outros fatores; respostas futuras e efeitos de crises de saúde pública; riscos de segurança cibernética; mudanças nas leis, regulamentos e tarifas aplicáveis do governo dos EUA e de outros países; nossa capacidade de implementar com sucesso nossa estratégia de aquisições ou integrar as empresas adquiridas; dificuldades e custos com a proteção de patentes e outros direitos de propriedade; nível da nossa dívida, nossa capacidade de lidar com a nossa dívida e as restrições nos nossos contratos de dívida; e quaisquer fatores adicionais incluídos no nosso Relatório Anual no Formulário 10–K do exercício fiscal encerrado em 30 de junho de 2024, arquivado na Comissão de Valores Mobiliários (a “SEC”) em 9 de setembro de 2024, incluindo na seção intitulada “Fatores de Risco” no Item 1A da Parte I de tal relatório, bem como nos nossos outros registros públicos na SEC. Fatores de risco adicionais podem ser identificados ocasionalmente nos nossos futuros documentos. Além disso, os resultados reais podem ser diferentes devido aos riscos e incertezas adicionais que não sejam do nosso conhecimento no momento ou que não sejam considerados como relevantes para os nossos negócios. Devido a tudo isso, os investidores não devem depositar confiança indevida em qualquer declaração voltada para o futuro. As declarações de previsão que fazemos são válidas somente a partir da data em que são feitas. Rejeitamos expressamente qualquer intenção ou obrigação de atualizar qualquer declaração de previsão a partir da data de hoje para adequar tais declarações a resultados reais ou mudanças na nossa opinião ou expectativas, exceto conforme exigido por lei ou pelas regras da Nasdaq Stock Market, LLC. Caso façamos alguma atualização ou correção de quaisquer declarações de previsão, os investidores não devem inferir que faremos outras atualizações ou correções.

Contato de Mídia da Lantronix:         
[email protected] 
949–212–0960 

Contato para Analista e Investidor da Lantronix:         
[email protected]


GLOBENEWSWIRE (Distribution ID 9513766)

Lantronix Solution Powers U.S. Army-Approved Teal Drones, a Red Cat Holdings Co., Unlocking Secure Edge AI Growth Opportunity

IRVINE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that its TAA– and NDAA–compliant solution was selected by Teal Drones, a Red Cat Holdings Inc. (NASDAQ: RCAT) company, for production of its Black Widow™ drones under the U.S. Army’s Short–Range Reconnaissance (SRR) Program. Lantronix has already initiated production shipments, providing early revenue visibility and underscoring Lantronix’s role as a trusted technology partner for mission‑critical defense applications.

The Lantronix solution, based on the Qualcomm® Dragonwing™ QRB5165 processor, delivers advanced Edge AI processing while meeting stringent U.S. security requirements, enabling full TAA and NDAA compliance for deployment in sensitive Department of Defense (DoD) missions. The combination of AI performance and compliance creates a sustainable advantage for Lantronix in the rapidly expanding defense and autonomous systems market.

As part of a select group of Blue UAS–approved small Unmanned Aerial Systems (sUAS) vendors, Teal Drones must meet rigorous cybersecurity, operational and safety standards for DoD use. Lantronix’s compliant solution enables Teal to meet these requirements, positioning its Black Widow drones for deployment in frontline missions.

“Black Widow drones are redefining what’s possible for small unmanned systems, giving today’s warfighters real–time intelligence and the operational edge they need on the modern battlefield,” said Jeff Thompson, CEO of Red Cat. “Lantronix’s solution enables us to meet the U.S. Army’s rigorous TAA and NDAA compliance standards under the SRR Program — a level of assurance few providers can match.”

With the global drone market projected to reach $57.8 billion by 2030 (Drone Industry Insights’ 2025–2030 Global Drone Market Report), Lantronix’s presence in the secure defense and commercial drone segment creates multi–year, high–margin growth opportunities.

“Lantronix has established itself as a leader in the Edge AI market, delivering innovative, compliance‑driven solutions for the growing drone sector,” said Saleel Awsare, CEO and president of Lantronix. “Our collaboration with Teal Drones underscores our ability to bring secure, high‑performance products to market at scale, creating long‑term opportunities with leading global brands.”

Lantronix solutions and Engineering Services combine embedded compute technology, compliance expertise and flexible software support to accelerate customer product development. This scalable platform approach not only enables rapid time‑to‑market for Teal Drones but also positions Lantronix to support future defense and industrial IoT programs requiring TAA and NDAA compliance.

Learn more about Lantronix’s Engineering Services, SOM solutions and additional Drone Applications at Lantronix.com.

About Lantronix   

Lantronix Inc. (Nasdaq: LTRX) is a global leader in Edge AI and Industrial IoT solutions, delivering intelligent computing, secure connectivity, and remote management for mission–critical applications. Serving high–growth markets, including smart cities, enterprise IT, and commercial and defense unmanned systems, Lantronix enables customers to optimize operations and accelerate digital transformation. Its comprehensive portfolio of hardware, software, and services powers applications from secure video surveillance and intelligent utility infrastructure to resilient out–of–band network management. By bringing intelligence to the network edge, Lantronix helps organizations achieve efficiency, security, and a competitive edge in today’s AI–driven world.

For more information, visit the Lantronix website.

About Red Cat Holdings Inc.

Red Cat (Nasdaq: RCAT) is a U.S.–based provider of advanced all–domain drone and robotic solutions for defense and national security. Through its wholly owned subsidiaries, Teal Drones and FlightWave Aerospace, Red Cat develops American–made hardware and software that support military, government, and public safety operations across air, land, and sea. Its Family of Systems, led by Black Widow™, delivers unmatched tactical capabilities in small unmanned aircraft systems (sUAS). Expanding into the maritime domain through Blue OPS, Inc., Red Cat is also innovating in uncrewed surface vessels (USVs) and autonomous underwater vehicles (AUVs), delivering integrated platforms designed to enhance safety and multi–domain mission effectiveness. Learn more at www.redcat.red.

©2025 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward–looking statements within the meaning of federal securities laws, including, without limitation, statements related to Lantronix products or leadership team. These forward–looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward–looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to the COVID–19 pandemic or other outbreaks, wars and recent tensions in Europe, Asia and the Middle East, or other factors; future responses to and effects of public health crises; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10–K for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on Sept. 9, 2024, including in the section entitled “Risk Factors” in Item 1A of Part I of that report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. In addition, actual results may differ as a result of additional risks and uncertainties about which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward–looking statements. The forward–looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward–looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward–looking statements, investors should not conclude that we will make additional updates or corrections.

Lantronix Media Contact:         
[email protected] 
949–212–0960 

Lantronix Analyst and Investor Contact:         
[email protected]


GLOBENEWSWIRE (Distribution ID 9513603)

Teal Drones, fabricant de drones approuvés par l’armée américaine et filiale de Red Cat Holdings, adopte la solution Lantronix, ouvrant ainsi de nouvelles perspectives de croissance pour l’IA sécurisée en périphérie de réseau

IRVINE, Californie, 18 août 2025 (GLOBE NEWSWIRE) — Lantronix Inc.– (NASDAQ : LTRX), leader mondial des solutions IdO de calcul et de connectivité pour l’IA en périphérie, a annoncé que sa solution, conforme aux normes TAA et NDAA, a été choisie par Teal Drones, filiale de Red Cat Holdings Inc. (NASDAQ : RCAT), pour la production de ses drones Black Widow™ dans le cadre du programme de reconnaissance à courte portée (SRR) de l’armée américaine. Lantronix a déjà débuté ses livraisons, offrant un premier aperçu de ses revenus et soulignant son rôle de partenaire technologique de confiance pour les applications cruciales dans le domaine de la défense.

La solution Lantronix, basée sur le processeur Qualcomm® Dragonwing™ QRB5165, offre des capacités avancées de traitement d’IA en périphérie tout en respectant les exigences strictes en matière de sécurité aux États–Unis, garantissant une conformité complète aux normes TAA et NDAA pour un déploiement dans des missions sensibles du Département de la Défense (DoD). Alliant performance en IA et conformité réglementaire, Lantronix se positionne durablement sur le marché en forte expansion de la défense et des systèmes autonomes. 

Faisant partie d’un groupe restreint de fournisseurs de petits systèmes d’aéronefs sans pilote (sUAS) approuvés par le programme Blue UAS, Teal Drones doit respecter des normes strictes en matière de cybersécurité, d’exploitation et de sécurité dans le cadre d'opérations du Département de la Défense (DoD). La solution conforme de Lantronix permet à Teal de satisfaire à ces exigences, préparant ses drones Black Widow à être déployés dans des missions en première ligne.

« Les drones Black Widow redéfinissent le potentiel des petits systèmes sans pilote, offrant aux combattants d’aujourd’hui des informations en temps réel et l’avantage opérationnel dont ils ont besoin sur le champ de bataille moderne », a déclaré Jeff Thompson, PDG de Red Cat. « La solution de Lantronix nous permet de satisfaire aux strictes normes de conformité TAA et NDAA de l’armée américaine dans le cadre du programme SRR — un niveau de fiabilité que peu de fournisseurs peuvent égaler. »

Avec un marché mondial des drones prévu pour atteindre 57,8 milliards de dollars d’ici 2030 (rapport 2025–2030 sur le marché mondial des drones de Drone Industry Insights), la présence de Lantronix dans le segment des drones sécurisés à usage défense et commercial ouvre des opportunités de croissance rentable sur plusieurs années.

—–« Lantronix s’est imposée comme un leader sur le marché de l’IA en périphérie, en proposant des solutions innovantes axées sur la conformité pour le secteur en croissance des drones », a déclaré Saleel Awsare, PDG et président de Lantronix. « Notre collaboration avec Teal Drones souligne notre capacité à commercialiser des produits sécurisés et à hautes performances à grande échelle, générant des opportunités à long terme avec des marques mondiales de premier plan, »

—Les solutions et services d’ingénierie de Lantronix allient technologies de calcul embarqué, expertise en matière de conformité et support logiciel flexible pour accélérer le développement des produits de ses clients. Cette approche de plateforme évolutive permet non seulement à Teal Drones de réduire considérablement le délai de mise sur le marché de ses produits, mais elle positionne également Lantronix pour soutenir de futurs programmes de défense et d’IoT industriel nécessitant une conformité aux normes TAA et NDAA.

Pour en savoir plus sur les services d’ingénierie, les solutions SOM et les autres applications pour drones de Lantronix, consultez le site Lantronix.com.

À propos de Lantronix   

Lantronix Inc. (Nasdaq : LTRX) est un leader mondial des solutions d’IA en périphérie et d’IdO industriel, offrant des capacités de calcul intelligentes, une connectivité sécurisée et une gestion à distance pour des applications critiques. Desservant des marchés en forte croissance, tels que les villes intelligentes, l’informatique d’entreprise et les systèmes sans pilote à usage commercial et militaire, Lantronix permet à ses clients d’optimiser leurs opérations et d’accélérer leur transformation numérique. Son portefeuille complet de matériel, de logiciels et de services permet d’assurer le bon fonctionnement d’applications allant de la vidéosurveillance sécurisée et des infrastructures intelligentes de services publics à la gestion réseau hors bande résiliente. En intégrant l’intelligence à la périphérie du réseau, Lantronix aide les organisations à gagner en efficacité, en sécurité et à acquérir un avantage concurrentiel dans un monde guidé par l’IA.

Pour en savoir plus, consultez le site Internet de Lantronix.

À propos de Red Cat Holdings Inc.

Red Cat (Nasdaq : RCAT) est un fournisseur américain de solutions avancées de drones et de robots tous domaines pour la défense et la sécurité nationale. Par l’intermédiaire de ses filiales à 100 %, Teal Drones et FlightWave Aerospace, Red Cat développe du matériel et des logiciels fabriqués aux États–Unis, destinés à soutenir les opérations militaires, gouvernementales et de sécurité publique sur terre, dans les airs et en mer. Sa famille de systèmes, notamment Black Widow™, offre des capacités tactiques inégalées en matière de systèmes d’aéronefs sans pilote de petite taille (sUAS). En développant ses activités dans le domaine maritime avec Blue OPS, Inc., Red Cat innove également dans les véhicules de surface sans équipage (USV) et les véhicules sous–marins autonomes (AUV), en proposant des plateformes intégrées conçues pour améliorer la sécurité et l’efficacité des missions multi–domaines. Pour en savoir plus, consultez le site www.redcat.red.

© 2025 Lantronix, Inc. Tous droits réservés. Lantronix est une marque déposée. Les autres marques et noms commerciaux appartiennent à leurs détenteurs respectifs.

Déclaration prospective au sens de la loi américaine Private Securities Litigation Reform Act de 1995 : le présent communiqué de presse contient des déclarations prospectives au sens des lois fédérales sur les valeurs mobilières, y compris, sans toutefois s’y limiter, des déclarations sur les produits ou le leadership de Lantronix. Ces déclarations prospectives sont fondées sur nos attentes actuelles et sont assujetties à des risques et incertitudes importants qui pourraient entraîner des écarts entre nos résultats réels, notre activité future, notre situation financière ou nos performances de nos résultats historiques ou de ceux exprimés ou induits dans toute déclaration prospective figurant dans le présent communiqué de presse. Ces risques et incertitudes comprennent, entre autres, des facteurs tels que les effets négatifs ou la dégradation de la situation économique régionale et mondiale ou l’instabilité du marché ciblant nos activités, y compris les effets sur les décisions d’achat de nos clients ; notre capacité à atténuer toute perturbation de nos propres chaînes d’approvisionnement et de celles de nos fournisseurs et distributeurs induite par la pandémie de COVID–19 ou d’autres épidémies ; les guerres et tensions récentes en Europe, en Asie et au Moyen–Orient, ou d’autres facteurs semblables ; les réponses à venir et les conséquences des crises de santé publique ; les risques en matière de cybersécurité ; les modifications apportées aux lois, réglementations et droits de douane en vigueur aux États–Unis et dans les pays étrangers ; notre aptitude à mettre en œuvre avec succès notre stratégie d’acquisition ou d’intégration des entreprises rachetées ; les enjeux et frais liés à la protection des droits de brevet et autres droits de propriété ; notre niveau d’endettement ; notre capacité à rembourser notre dette et les restrictions imposées à nos accords de dette ; ainsi que tout autre facteur supplémentaire repris dans notre rapport annuel sous le formulaire 10–K pour l’exercice clos le 30 juin 2024, déposé auprès de la Securities and Exchange Commission (la « SEC ») le 9 septembre 2024 dernier, y compris à la rubrique « Facteurs de risque » sous l’alinéa 1A de la Partie I de ce rapport, ainsi que dans nos autres documents publics déposés auprès de la SEC.  Des facteurs de risque supplémentaires peuvent être identifiés le cas échéant dans nos futurs dépôts. Par ailleurs, les résultats réels peuvent varier en raison de risques et incertitudes supplémentaires dont nous n’avons pas nécessairement conscience à ce jour ou que nous ne considérons pas comme majeurs pour nos activités. En conséquence, il est recommandé aux investisseurs de ne pas se fier indûment aux déclarations prospectives, lesquelles ne sont valables qu’à leur date de publication. Nous déclinons expressément toute intention ou obligation de les mettre à jour postérieurement à ce communiqué en vue de les adapter selon nos résultats réels ou les revirements intervenus dans nos avis ou attentes, sauf si la loi applicable ou les règles du Nasdaq Stock Market LLC l’exigent. Si nous actualisons ou corrigeons l’une quelconque de ces déclarations, les investisseurs ne sauraient tenir d’autres mises à jour ou révisions pour garanties.

Contact presse Lantronix :         
[email protected] 
949–212–0960 

Contact analystes et investisseurs de Lantronix :         
[email protected]


GLOBENEWSWIRE (Distribution ID 9513766)

Sexual Health Rights: Contradictions in East African Laws, Policies

Abortion is illegal in Uganda. Girls who get pregnant resort to deadly backstreet abortion providers. However, it is also criminal to provide safe abortion services. Credit: Wambi Michael/IPS

Abortion is illegal in Uganda. Girls who get pregnant resort to deadly backstreet abortion providers. However, it is also criminal to provide safe abortion services. Credit: Wambi Michael/IPS

By Wambi Michael
KAMPALA, Aug 18 2025 – Sarah Namukisa nearly missed her final year exams earlier this year. She was subjected to a mandatory pregnancy test—the 25-year-old student at the Medical Laboratory Training School in Jinja was then expelled because she was pregnant.

While Namukisa’s case sparked public criticism, activists say it was by no means an isolated incident.

Across Uganda and other East African countries, pregnant students continue to face expulsion, forced school dropout, and stigma in both public and private educational institutions.

Labila Sumaya Musoke, from the Initiative for Social and Economic Rights (ISER), told IPS that the widespread practice reflects deep-seated systemic discrimination and patriarchal control over young women’s bodies and futures

She said the expulsion mirrors systemic and institutional discrimination that international and regional human rights bodies have explicitly deemed unlawful and incompatible with human rights standards.

Namukisa was lucky that her case attracted the attention of the civil society and Uganda’s Equal Opportunities Commission. The commission ordered her school to rescind the expulsion. Many young women resort to deadly “backstreet” abortions in an effort to find ways to return to school or higher learning institutes. Abortion is still outlawed in Uganda and its neighbors—Kenya and Tanzania.

The most recent Demographic and Health Survey (DHS) datasets of the 12 East African countries found that the overall prevalence of adolescent pregnancy in East Africa was 54.6 percent. The survey concluded that it is vital to design public health interventions targeting higher-risk adolescent girls, particularly those from the poorest households, by enhancing maternal education and empowerment to reduce adolescent pregnancy and its complications.

Teenage pregnancy and motherhood rate in Kenya stands at 18 percent. This implies that about one in every five teenage girls between the ages of 15-19 years has either had a live birth or is pregnant with their first child.

The rate of teenage pregnancy has stagnated for over a decade in Uganda; it stood at 25 percent in 2006, at 24 percent in 2011 and now shows trends of rising at 25 percent. Teenage pregnancy in Tanzania is a significant public health issue, with 22 percent of women aged 15-19 having been pregnant, according to a 2022 Tanzania Demographic and Health Survey.

Rosemary Kirui, the Legal Advisor at the Center for Reproductive Rights—which works in seven countries, including Uganda—said the enjoyment of the Sexual Reproductive Health rights has been limited by barriers related to the legal and policy framework.

“We have a legal environment that has restrictive laws that criminalize some SHRH services. Most of the laws were adopted or inherited from the colonialists. And most of the countries have not changed the laws. So you will find that the penal code is similar, giving a blanket criminalization of abortion. So you will find this is being interpreted narrowly in many African countries,” said Kirui.

She told IPS that the other aspect of restrictive laws is the age of consent, where there is a mandatory third-party requirement for adolescents seeking information and sexual reproduction health services.

Primer Kwagala, a Ugandan Lawyer whose organization, Women Pro Bono Initiative (WPI), has been litigating for access to SHR services, told IPS that the country maintains restrictions on abortion.

“We are saying that 16 women are dying each day due to lack of services in public health facilities. And there are those who are dying in communities due to unsafe abortion. We have on our law books outdated colonial policies preventing health workers from providing life-saving services.”

Uganda’s constitution says that no one can take the life of an unborn child except in exceptional circumstances.

“For many women to exercise autonomy over their bodies and to say, ‘I cannot carry this pregnancy; I need an abortion,’ they cannot go ahead and have that discussion. The first thing the health worker will say is, ‘I don’t want to go to prison,’” said Kwagala.

The Ministry of Health in Uganda has issued guidelines allowing safe abortions in cases of defilement, rape, and incest. But the guidelines, according to Kwagala, are more on paper than in practice.

In 2020, a ruling by the African Committee of Experts on the Rights and Welfare of the Child (ACERWC) against the Republic of Tanzania found that Tanzania’s policy of expelling pregnant schoolgirls constituted a violation of the African Charter on the Rights and Welfare of the Child, particularly the rights to education, health, dignity, and non-discrimination.

Six girls who were pregnant were expelled from the school. The committee urged Tanzania to reform its education policies.

Dr. Godfrey Kangaude, an expert on Sexual Reproductive Health and Rights based in Malawi, said there is a tussle between the gatekeepers who think the SHR issues are for the civil society to handle.

“But I think this is closest to us. Sex and reproduction are relevant to everyone,” said Kangaude while speaking to the East Africa Law Society on litigating for sexual health rights.

He said sexual and reproductive justice is closely interrelated with finance and labor justice and generally the overall well-being of humans.

Kagaunde explained that in Malawi and other countries in the region, there are anomalies when it comes to the age of consent.

“In Malawi, the law says an adult cannot have sex with a child. Okay, we want to protect children. Isn’t it? But the line has been so rigid that an 18-year-old boy can’t have sex with a 17-year-old girl, because a 17-year-old is a minor and an 18-year-old is an adult. We understand that we want to protect people from harmful sexual conduct, especially children, but the law shouldn’t just be arbitrary. It should take into account that the 17-year-old and 18-year-old are peers.”

Criminalization of Consensual Sex 

Kangaunde and others argue that rights-based reform is needed. Laws should be gender-neutral, orientation-neutral, and distinguish exploitative adult–child sex from non-exploitative peer sex. Kangaude points to alternatives like multi-stage consent and close-in-age (“Romeo & Juliet”) exemptions.

Kangaunde and others have been criticized over their stance on the age of consent to sex and access for individuals younger than 18 to access contraceptives and safe abortion services.

“But look, there is a 19-year-old boy who is being charged with the offense of having sex with a girlfriend of 17. I mean, for him, life just went crazy. He is at school, and he had to stop schooling,” said Kangaude, the director at Nyale Institute. His institute provides legal support and engages in strategic litigation to protect and promote sexual and reproductive health rights.

Activists have since 2017 been pushing for a regional Sexual Reproductive Health Rights law. They contend that across East Africa, sexual and reproductive health rights have been narrowly defined as standalone rights.

If enacted, it would require the EAC member states to harmonize provisions on sexual and reproductive health services and information.

The bill has, however, faced significant resistance based especially on social and cultural barriers. The resistance has focused on aspects of comprehensive sex education for teenagers and provisions regarding legal abortion.

Dr. Tom Mulisa, a human rights and constitutional law researcher based at the University of Rwanda, told IPS that sexual and reproductive health rights are broad.

“Constitutions have those rights, and national health laws and policies have those rights, we are talking about the right to health, which most constitutions have, and we are talking about the right to privacy, the right to information, and sexual and reproductive health rights,” he said.

The partner states have ratified the Maputo protocol, which allows for the termination of pregnancy. The protocol is the main regional instrument that advances women’s rights especially sexual and reproductive health rights. The protocol also provides for elimination of discrimination and prohibition of harmful practices, such as female genital cutting.

Within the region, some countries have ratified the protocol, others have not and others have ratified it with reservations. Enforcement of the protocol has been split, making it difficult for all to enjoy the broader rights therein.

Kenya made reservations about Article (14), which provides for safe and legal abortion. Kenya’s constitution, on the other hand, provides for a right to legal and safe abortion when the life of the mother or fetus is at threat.

Learning From Advances in Rwanda

Rwanda has made significant progress in improving the sexual and reproductive health (SRH) of its population, especially young individuals. Like many countries in the region, it had post-colonial laws. It embarked on reform since 2009. The reforms laid the groundwork for what many describe as a flexible system.

Earlier this month, Rwanda’s Parliament passed a new law granting adolescent girls the right to access Sexual and Reproductive Health (SRH) services—particularly family planning—without requiring parental consent. It lowered the legal age to access contraceptives from 18-15.

Mulisa stated that the country modified its new penal code by eliminating the court’s requirement for an abortion. The penal code also included sexual reproductive health rights.

“Previously, the government held the right to health, while individuals were obligated to comply with it. But now the constitution has an explicit right to health,” revealed Mulisa, the founder of the Great Lakes Initiative For Human Rights and Development, which does public interest litigation in Rwanda.

It is now a crime under the penal code in Rwanda if a woman is denied access to contraceptives. And there are fewer restrictions on safe abortion following the removal of the court order requirement.

Rwanda’s ministerial order on abortion defines the right to health more broadly, incorporating the scope outlined by the WHO.

According to the WHO, the right to health includes four essential, interrelated elements: availability, accessibility, acceptability, and quality.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById({js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);